Outpace Bio is at the forefront of cell therapy innovation, focusing on solid tumors through advanced AI-powered protein design. The company aims to enhance immune cell functionality to tackle significant challenges in cancer treatment, such as tumor access and antigen escape. With a multidisciplinary team of experts in computational protein design, synthetic biology, and immunology, Outpace Bio is dedicated to transforming engineered T cell therapies. Located in Seattle's biotech hub, the company fosters a culture of respect and inclusion, emphasizing diversity in its workforce. Recently, Outpace Bio secured $144 million in Series B financing to accelerate its pipeline of programmed T cell therapies, including its lead candidate OPB-101 for advanced ovarian cancers. The company is committed to groundbreaking research that has the potential to change lives globally.